SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 748.41 |
| Enterprise Value ($M) | 734.08 |
| Book Value ($M) | 40.92 |
| Book Value / Share | 1.05 |
| Price / Book | 18.29 |
| NCAV ($M) | 40.45 |
| NCAV / Share | 1.04 |
| Price / NCAV | 18.50 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.31 |
| Return on Assets (ROA) | -0.68 |
| Return on Equity (ROE) | -0.75 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.14 |
| Current Ratio | 5.14 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 50.22 |
| Assets | 50.70 |
| Liabilities | 9.77 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -56.76 |
| Net Income | -54.42 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -50.87 |
| Cash from Investing | 24.23 |
| Cash from Financing | 30.19 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Fmr Llc | 12.75 | 173.20 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 7.60 | 7.68 | |
| 13G/A | Point72 Asset Management, L.P. | 3.80 | -34.00 | |
| 13G/A | Cormorant Asset Management, LP | 9.99 | 18.84 | |
| 13G/A | Prosight Management, LP | 0.00 | -100.00 | |
| 13G/A | HBM Healthcare Investments (Cayman) Ltd. | 0.00 | -100.00 | |
| 13G/A | Farallon Capital Partners, L.P. | 9.99 | 55.58 | |
| 13D/A | Pfizer Inc | 0.00 | -100.00 | |
| 13G/A | Integrated Core Strategies (us) Llc | 0.00 | -99.33 | |
| 13G | Ra Capital Management, L.p. | 8.70 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 17,626 | 153,688 | 11.47 | |
| 37,802 | 119,501 | 31.63 | |
| 41,277 | 138,734 | 29.75 | |
| 63,742 | 202,318 | 31.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KOD – Kodiak Sciences Inc. | KROS – Keros Therapeutics, Inc. |
| KYMR – Kymera Therapeutics, Inc. | LGND – Ligand Pharmaceuticals Incorporated |
| LNTH – Lantheus Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io